Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder closely related to immunity. An important aspect of the pathogenesis of PD is the interaction between α-synuclein and a series of immune cells. Studies have shown that accumulation of α-synuclein can induce an autoimmune response that accelera...
Enregistré dans:
Auteurs principaux: | , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/0010b87d05e84d249d15557ca42e2e65 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
id |
oai:doaj.org-article:0010b87d05e84d249d15557ca42e2e65 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0010b87d05e84d249d15557ca42e2e652021-11-05T08:36:16ZAlpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease1663-436510.3389/fnagi.2021.769506https://doaj.org/article/0010b87d05e84d249d15557ca42e2e652021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fnagi.2021.769506/fullhttps://doaj.org/toc/1663-4365Parkinson’s disease (PD) is a neurodegenerative disorder closely related to immunity. An important aspect of the pathogenesis of PD is the interaction between α-synuclein and a series of immune cells. Studies have shown that accumulation of α-synuclein can induce an autoimmune response that accelerates the progression of PD. This study discusses the mechanisms underlying the interaction between α-synuclein and the immune system. During the development of PD, abnormally accumulated α-synuclein becomes an autoimmune antigen that binds to Toll-like receptors (TLRs) that activate microglia, which differentiate into the microglia type 1 (M1) subtype. The microglia activate intracellular inflammatory pathways, induce the release of proinflammatory cytokines, and promote the differentiation of cluster of differentiation 4 + (CD4 +) T cells into proinflammatory T helper type 1 (Th1) and T helper type 17 (Th17) subtypes. Given the important role of α-synuclein in the immune system of the patients with PD, identifying potential targets of immunotherapy related to α-synuclein is critical for slowing disease progression. An enhanced understanding of immune-associated mechanisms in PD can guide the development of associated therapeutic strategies in the future.Ruichen SuTian ZhouFrontiers Media S.A.articleParkinson’s disease (PD)α-synucleinmicrogliaT cellstherapeuticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENFrontiers in Aging Neuroscience, Vol 13 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Parkinson’s disease (PD) α-synuclein microglia T cells therapeutics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 |
spellingShingle |
Parkinson’s disease (PD) α-synuclein microglia T cells therapeutics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Ruichen Su Tian Zhou Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease |
description |
Parkinson’s disease (PD) is a neurodegenerative disorder closely related to immunity. An important aspect of the pathogenesis of PD is the interaction between α-synuclein and a series of immune cells. Studies have shown that accumulation of α-synuclein can induce an autoimmune response that accelerates the progression of PD. This study discusses the mechanisms underlying the interaction between α-synuclein and the immune system. During the development of PD, abnormally accumulated α-synuclein becomes an autoimmune antigen that binds to Toll-like receptors (TLRs) that activate microglia, which differentiate into the microglia type 1 (M1) subtype. The microglia activate intracellular inflammatory pathways, induce the release of proinflammatory cytokines, and promote the differentiation of cluster of differentiation 4 + (CD4 +) T cells into proinflammatory T helper type 1 (Th1) and T helper type 17 (Th17) subtypes. Given the important role of α-synuclein in the immune system of the patients with PD, identifying potential targets of immunotherapy related to α-synuclein is critical for slowing disease progression. An enhanced understanding of immune-associated mechanisms in PD can guide the development of associated therapeutic strategies in the future. |
format |
article |
author |
Ruichen Su Tian Zhou |
author_facet |
Ruichen Su Tian Zhou |
author_sort |
Ruichen Su |
title |
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease |
title_short |
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease |
title_full |
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease |
title_fullStr |
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease |
title_full_unstemmed |
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease |
title_sort |
alpha-synuclein induced immune cells activation and associated therapy in parkinson’s disease |
publisher |
Frontiers Media S.A. |
publishDate |
2021 |
url |
https://doaj.org/article/0010b87d05e84d249d15557ca42e2e65 |
work_keys_str_mv |
AT ruichensu alphasynucleininducedimmunecellsactivationandassociatedtherapyinparkinsonsdisease AT tianzhou alphasynucleininducedimmunecellsactivationandassociatedtherapyinparkinsonsdisease |
_version_ |
1718444449036500992 |